Oseltamivir resistance among influenza viruses in northern Viet Nam, 2009–2012.
DOI:
https://doi.org/10.5365/wpsar.2013.4.1.010Abstract
Background. Antiviral resistance has been reported in seasonal influenza A viruses and avian influenza A/H5N1 viruses in Vietnam, raising concerns about the efficacy of treatment.
Methods. We analyzed isolates from influenza-positive samples collected from influenza-like illness patients at sentinel clinics of NISS in northern Vietnam and isolates from patients with confirmed A/H5N1 infections during 2009-2012. Pyrosequencing was used to detect mutations: H275Y (for A/H1N1 and A/H5N1), E119V(for A/H3N2) and I117V(for A/H5N1). The neuraminidase inhibition (NAI) assay was used to determine the IC50 values for all influenza A and B isolates.
Results. All 19 seasonal A/H1N1 samples collected in 2009 contained the H275Y neuraminidase substitution, and the IC50 values observed from six isolates (6/19) were 1000-fold higher than baseline. A total of 215 samples and 27 A/H1N1pdm09 isolates were tested; we determined H275Y on three (0.7%) samples and referred with IC50 values ranging from 118.59 to 127.91 nM (i.e. >200-fold higher than baseline). Other subtypes A/H3N2 (100 samples) and A/H5N1 ( seven isolats) were determined to be sensitive to oseltamivir by both pyrosequencing and NAI assays.. Influenza B (67 isolates) was determined to be sensitive to oseltamivir as IC50 values were within the susceptibility range.
Discussion.
Mutations associated with oseltamivir-resistance were identified in seasonal influenza A/H1N1 and A/H1N1pdm09 viruses from northern Vietnam. Seasonal influenza vaccines and human H5N1 vaccines are not currently available, thus, underscoring the need for effective treatment. To control the efficacy of oseltamivir for treatment, active surveillance for oseltamivir resistance among influenza viruses circulating in Vietnam should be expanded.
Downloads
Published
How to Cite
Issue
Section
License
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
When the Licensor is an intergovernmental organization, disputes will be resolved by mediation and arbitration unless otherwise agreed.
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation.
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.